Most U.S. residents are unaware there are shortages in the availability of cancer drugs, such as those for multiple myeloma, a type of cancer…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
A combination of Idera Pharmaceuticals’s treatment candidate tilsotolimod plus Yervoy (ipilimumab) is able to reduce tumors in a group of patients with refractory…
Adding Pomalyst (pomalidomide) to a combination of Velcade (bortezomib) and dexamethasone significantly extended…
Janssen has decided to discontinue a Phase 1 trial assessing Darzalex (daratumumab) in combination with JNJ-63723283 — an anti-PD-1 antibody — in multiple myeloma patients, …
A combination of Darzalex (daratumumab) plus Kyprolis (carfilzomib) and dexamethasone is well-tolerated and may be effective in multiple myeloma patients who fail to respond to treatment…
Researchers in Canada are studying how to reduce the risks associated with the treatment of multiple myeloma by improving the safety and efficacy of…
